Literature DB >> 23432687

Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.

Tara L Chen1, Elihu H Estey, Megan Othus, Kelda M Gardner, Lauren J Markle, Roland B Walter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23432687      PMCID： PMC3863328          DOI： 10.3109/10428194.2013.777836

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials.

Authors:  P F Thall; E H Estey; H G Sung
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Adaptive clinical trials in oncology.

Authors:  Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

3.  Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.

Authors:  Peter F Thall; John D Cook; Elihu H Estey
Journal:  J Biopharm Stat       Date:  2006       Impact factor: 1.051

4.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

Authors:  Steven M Kornblau; Deborah E Banker; Derek Stirewalt; Danny Shen; Elizabeth Lemker; Srdan Verstovsek; Zeev Estrov; Stefan Faderl; Jorge Cortes; Miloslav Beran; C Ellen Jackson; Wenjing Chen; Elihu Estey; Frederick R Appelbaum
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

Authors:  M S Tallman; S Lee; B I Sikic; E Paietta; P H Wiernik; J M Bennett; J M Rowe
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

7.  Dose-finding based on efficacy-toxicity trade-offs.

Authors:  Peter F Thall; John D Cook
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

8.  P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.

Authors:  Laura Connelly-Smith; Joanne Pattinson; Martin Grundy; Shili Shang; Claire Seedhouse; Nigel Russell; Monica Pallis
Journal:  Exp Hematol       Date:  2007-10-17       Impact factor: 3.084

Review 9.  Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.

Authors:  Daruka Mahadevan; Alan F List
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

10.  Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.

Authors:  Deborah E Banker; Sasha J Mayer; Henry Y Li; Cheryl L Willman; Frederick R Appelbaum; Richard A Zager
Journal:  Blood       Date:  2004-05-25       Impact factor: 22.113
View more
  4 in total

1.  Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Authors:  Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Paul C Hendrie; Mary-Elizabeth M Percival; Pamela S Becker; Heather A Smith; Vivian G Oehler; Johnnie J Orozco; Ryan D Cassaday; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Elihu H Estey; Roland B Walter
Journal:  Haematologica       Date:  2018-11-08       Impact factor: 9.941

Review 2.  Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Authors:  Galen Leung; Marianna Papademetriou; Shannon Chang; Francis Arena; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 3.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

4.  Implementing the EffTox dose-finding design in the Matchpoint trial.

Authors:  Kristian Brock; Lucinda Billingham; Mhairi Copland; Shamyla Siddique; Mirjana Sirovica; Christina Yap
Journal:  BMC Med Res Methodol       Date:  2017-07-20       Impact factor: 4.615
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.